Literature DB >> 26148707

The right drugs at the right time for the right patient: the MD Anderson precision oncology decision support platform.

Amber Johnson1, Jia Zeng1, Ann M Bailey1, Vijaykumar Holla1, Beate Litzenburger1, Humberto Lara-Guerra1, Gordon B Mills2, John Mendelsohn3, Kenna R Shaw1, Funda Meric-Bernstam4.   

Abstract

The development of resources for clinical interpretation of cancer-associated genetic alterations has significantly lagged behind the technical developments enabling their detection in a time- and cost-efficient manner. The lack of scientific and informatics decision support for oncologists can lead to no action being taken or suboptimal therapeutic choices being made, which could affect the clinical outcome of a patient as well as convoluting research findings from clinical trials. In this article, we describe the precision oncology decision support (PODS) platform developed within The Sheikh Khalifa Bin Zayed Al Nahyan Institute for Personalized Cancer Therapy (IPCT) at MD Anderson Cancer Center; the platform aims to bridge the gap between molecular alteration detection and identification of appropriate treatments.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26148707      PMCID： PMC5648066          DOI： 10.1016/j.drudis.2015.05.013

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN： 1359-6446            Impact factor:   7.851


  32 in total

1.  2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.

Authors:  Ian Smith; Marion Procter; Richard D Gelber; Sébastien Guillaume; Andrea Feyereislova; Mitch Dowsett; Aron Goldhirsch; Michael Untch; Gabriella Mariani; Jose Baselga; Manfred Kaufmann; David Cameron; Richard Bell; Jonas Bergh; Robert Coleman; Andrew Wardley; Nadia Harbeck; Roberto I Lopez; Peter Mallmann; Karen Gelmon; Nicholas Wilcken; Erik Wist; Pedro Sánchez Rovira; Martine J Piccart-Gebhart
Journal:  Lancet       Date:  2007-01-06       Impact factor: 79.321

2.  Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.

Authors:  Scott R Daigle; Edward J Olhava; Carly A Therkelsen; Aravind Basavapathruni; Lei Jin; P Ann Boriack-Sjodin; Christina J Allain; Christine R Klaus; Alejandra Raimondi; Margaret Porter Scott; Nigel J Waters; Richard Chesworth; Mikel P Moyer; Robert A Copeland; Victoria M Richon; Roy M Pollock
Journal:  Blood       Date:  2013-06-25       Impact factor: 22.113

Review 3.  Information technology and precision medicine.

Authors:  Pamela H Carney
Journal:  Semin Oncol Nurs       Date:  2014-05       Impact factor: 2.315

4.  CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors.

Authors:  Ya-Ping Chen; Hui-Ju Lin; Jiann-Shiuh Chen; Ming-Ying Tsai; Hsing-Pang Hsieh; Jang-Yang Chang; Nai-Feng Chen; Kung-Chao Chang; Wen-Tsung Huang; Wu-Chou Su; Shu-Ting Yang; Wen-Chang Chang; Liang-Yi Hung; Tsai-Yun Chen
Journal:  Int J Cancer       Date:  2014-01-13       Impact factor: 7.396

5.  NCCN Task Force report: Evaluating the clinical utility of tumor markers in oncology.

Authors:  Phillip G Febbo; Marc Ladanyi; Kenneth D Aldape; Angelo M De Marzo; M Elizabeth Hammond; Daniel F Hayes; A John Iafrate; R Kate Kelley; Guido Marcucci; Shuji Ogino; William Pao; Dennis C Sgroi; Marian L Birkeland
Journal:  J Natl Compr Canc Netw       Date:  2011-11       Impact factor: 11.908

Review 6.  Targeting mutant fibroblast growth factor receptors in cancer.

Authors:  Heidi Greulich; Pamela M Pollock
Journal:  Trends Mol Med       Date:  2011-03-01       Impact factor: 11.951

Review 7.  A decision support framework for genomically informed investigational cancer therapy.

Authors:  Funda Meric-Bernstam; Amber Johnson; Vijaykumar Holla; Ann Marie Bailey; Lauren Brusco; Ken Chen; Mark Routbort; Keyur P Patel; Jia Zeng; Scott Kopetz; Michael A Davies; Sarina A Piha-Paul; David S Hong; Agda Karina Eterovic; Apostolia M Tsimberidou; Russell Broaddus; Elmer V Bernstam; Kenna R Shaw; John Mendelsohn; Gordon B Mills
Journal:  J Natl Cancer Inst       Date:  2015-04-11       Impact factor: 13.506

8.  Randomised proof-of-concept phase II trial comparing targeted therapy based on tumour molecular profiling vs conventional therapy in patients with refractory cancer: results of the feasibility part of the SHIVA trial.

Authors:  C Le Tourneau; X Paoletti; N Servant; I Bièche; D Gentien; T Rio Frio; A Vincent-Salomon; V Servois; J Romejon; O Mariani; V Bernard; P Huppe; G Pierron; F Mulot; C Callens; J Wong; C Mauborgne; E Rouleau; C Reyes; E Henry; Q Leroy; P Gestraud; P La Rosa; L Escalup; E Mitry; O Trédan; J-P Delord; M Campone; A Goncalves; N Isambert; C Gavoille; M Kamal
Journal:  Br J Cancer       Date:  2014-04-24       Impact factor: 7.640

9.  The need for clinical decision support integrated with the electronic health record for the clinical application of whole genome sequencing information.

Authors:  Brandon M Welch; Kensaku Kawamoto
Journal:  J Pers Med       Date:  2013-12-18

10.  Whole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.

Authors:  Eliezer M Van Allen; Nikhil Wagle; Petar Stojanov; Danielle L Perrin; Kristian Cibulskis; Sara Marlow; Judit Jane-Valbuena; Dennis C Friedrich; Gregory Kryukov; Scott L Carter; Aaron McKenna; Andrey Sivachenko; Mara Rosenberg; Adam Kiezun; Douglas Voet; Michael Lawrence; Lee T Lichtenstein; Jeff G Gentry; Franklin W Huang; Jennifer Fostel; Deborah Farlow; David Barbie; Leena Gandhi; Eric S Lander; Stacy W Gray; Steven Joffe; Pasi Janne; Judy Garber; Laura MacConaill; Neal Lindeman; Barrett Rollins; Philip Kantoff; Sheila A Fisher; Stacey Gabriel; Gad Getz; Levi A Garraway
Journal:  Nat Med       Date:  2014-05-18       Impact factor: 53.440
View more
  31 in total

1.  Database of evidence for precision oncology portal.

Authors:  Sam Q Sun; R Jay Mashl; Sohini Sengupta; Adam D Scott; Weihua Wang; Prag Batra; Liang-Bo Wang; Matthew A Wyczalkowski; Li Ding
Journal:  Bioinformatics       Date:  2018-12-15       Impact factor: 6.937

Review 2.  Machine learning approaches to drug response prediction: challenges and recent progress.

Authors:  George Adam; Ladislav Rampášek; Zhaleh Safikhani; Petr Smirnov; Benjamin Haibe-Kains; Anna Goldenberg
Journal:  NPJ Precis Oncol       Date:  2020-06-15

Review 3.  Precision Oncology Decision Support: Current Approaches and Strategies for the Future.

Authors:  Katherine C Kurnit; Ecaterina E Ileana Dumbrava; Beate Litzenburger; Yekaterina B Khotskaya; Amber M Johnson; Timothy A Yap; Jordi Rodon; Jia Zeng; Md Abu Shufean; Ann M Bailey; Nora S Sánchez; Vijaykumar Holla; John Mendelsohn; Kenna Mills Shaw; Elmer V Bernstam; Gordon B Mills; Funda Meric-Bernstam
Journal:  Clin Cancer Res       Date:  2018-02-02       Impact factor: 12.531

4.  Automated identification of molecular effects of drugs (AIMED).

Authors:  Safa Fathiamini; Amber M Johnson; Jia Zeng; Alejandro Araya; Vijaykumar Holla; Ann M Bailey; Beate C Litzenburger; Nora S Sanchez; Yekaterina Khotskaya; Hua Xu; Funda Meric-Bernstam; Elmer V Bernstam; Trevor Cohen
Journal:  J Am Med Inform Assoc       Date:  2016-04-23       Impact factor: 4.497

5.  Physician interpretation of genomic test results and treatment selection.

Authors:  Lauren L Brusco; Chetna Wathoo; Kenna R Mills Shaw; Vijaykumar R Holla; Ann M Bailey; Amber M Johnson; Yekaterina B Khotskaya; Beate C Litzenburger; Nora S Sanchez; Jia Zeng; Elmer V Bernstam; Cathy Eng; Bryan K Kee; Rodabe N Amaria; Mark J Routbort; Gordon B Mills; John Mendelsohn; Funda Meric-Bernstam
Journal:  Cancer       Date:  2017-11-22       Impact factor: 6.860

6.  mTCTScan: a comprehensive platform for annotation and prioritization of mutations affecting drug sensitivity in cancers.

Authors:  Mulin Jun Li; Hongcheng Yao; Dandan Huang; Huanhuan Liu; Zipeng Liu; Hang Xu; Yiming Qin; Jeanette Prinz; Weiyi Xia; Panwen Wang; Bin Yan; Nhan L Tran; Jean-Pierre Kocher; Pak C Sham; Junwen Wang
Journal:  Nucleic Acids Res       Date:  2017-07-03       Impact factor: 16.971

Review 7.  Operationalization of Next-Generation Sequencing and Decision Support for Precision Oncology.

Authors:  Jia Zeng; Amber Johnson; Md Abu Shufean; Michael Kahle; Dong Yang; Scott E Woodman; Thuy Vu; Shhyam Moorthy; Vijaykumar Holla; Funda Meric-Bernstam
Journal:  JCO Clin Cancer Inform       Date:  2019-09

8.  "Personalized Cancer Therapy": A Publicly Available Precision Oncology Resource.

Authors:  Katherine C Kurnit; Ann M Bailey; Jia Zeng; Amber M Johnson; Md Abu Shufean; Lauren Brusco; Beate C Litzenburger; Nora S Sánchez; Yekaterina B Khotskaya; Vijaykumar Holla; Amy Simpson; Gordon B Mills; John Mendelsohn; Elmer Bernstam; Kenna Shaw; Funda Meric-Bernstam
Journal:  Cancer Res       Date:  2017-11-01       Impact factor: 12.701

9.  Rapamycin - mTOR + BRAF = ? Using relational similarity to find therapeutically relevant drug-gene relationships in unstructured text.

Authors:  Safa Fathiamini; Amber M Johnson; Jia Zeng; Vijaykumar Holla; Nora S Sanchez; Funda Meric-Bernstam; Elmer V Bernstam; Trevor Cohen
Journal:  J Biomed Inform       Date:  2019-01-04       Impact factor: 6.317

10.  Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA.

Authors:  Nora S Sánchez; Michael P Kahle; Ann Marie Bailey; Chetna Wathoo; Kavitha Balaji; Mehmet Esat Demirhan; Dong Yang; Milind Javle; Ahmed Kaseb; Cathy Eng; Vivek Subbiah; Filip Janku; Victoria M Raymond; Richard B Lanman; Kenna R Mills Shaw; Funda Meric-Bernstam
Journal:  JCO Precis Oncol       Date:  2019-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.